Journal of Clinical Hepatology
This article aims to explore the application value of the G-GADA model in the diagnosis of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC). Based on serum markers AFP, DCP, GP73, and clinical variables (age, gender), a new diagnostic model G-GADA is constructed and its diagnostic efficacy in different subgroups is evaluated. The results show that the model exhibits a high AUC value in the overall population, AFP low-expression patients, and liver cirrhosis patients (modeling group 0.884~0.901, validation group 0.851~0.885), significantly better than the classic GALAD model. The innovation lies in the introduction of the emerging marker GP73 to replace AFP-L3%, optimizing the original model structure, while maintaining a similar variable framework and improving the diagnostic sensitivity for AFP-negative or liver cirrhosis background patients. In addition, the study also confirms the association of GP73 with tumor progression, which has potential clinical significance. This model provides a more optimal non-invasive diagnostic tool for HBV-HCC, especially for early or difficult-to-diagnose cases.
The main significance of this study lies in the construction and verification of an optimized hepatocellular carcinoma (HCC) diagnostic model - the G-GADA model, to improve the accuracy of early diagnosis of HCC. HCC is a highly prevalent malignant tumor worldwide, and most cases in China are related to chronic hepatitis B, often leading to delayed diagnosis and treatment due to the lack of typical symptoms. Although markers such as AFP and DCP have been used in clinical practice, their sensitivity and specificity are limited. In recent years, GP73, as a new serum marker, has significantly increased in HCC patients and has high diagnostic value. Based on variables such as age, gender, log10GP73, log10AFP, and log10DCP, the G-GADA model is established, with the core variable selection similar to the existing GALAD model but incorporating GP73, a more promising indicator, to enhance the identification ability of HCC. The study results show that the levels of these markers show a gradual increase trend among chronic hepatitis B (CHB), liver cirrhosis (LC), and HCC patients, and are related to tumor stage, size, and metastasis, indicating their clinical relevance. By comparing the modeling and validation groups, the stability of the model is further confirmed. This model is expected to become a non-invasive, efficient screening tool, especially suitable for early warning of HCC in the background of hepatitis B. In the future, it needs to be further verified for its generalizability in multicenter large sample cohorts.
Objective: To establish an optimized diagnostic model for hepatocellular carcinoma (HCC), designated as G-GADA, in chronic hepatitis …
